Summary of AngioDynamics FY Conference Call (January 14, 2026) Company Overview - **Company**: AngioDynamics (NasdaqGS: ANGO) - **Industry**: Medical Technology (MedTech) and Medical Devices - **Transformation**: Over the past five years, AngioDynamics has shifted from an interventional radiology-based company to a more diversified MedTech portfolio, focusing on larger, addressable markets [2][3] Key Points and Arguments Portfolio Transformation - The company has undergone significant transformation, divesting from slow or undifferentiated markets to focus on a scientific-based MedTech portfolio [3][4] - Achieved a five-year compound annual growth rate (CAGR) of approximately 25% in MedTech markets during this transformation [4] Operating Segments - AngioDynamics operates in two segments: - **MedTech Portfolio**: Focused on growth and innovation - **MedDevice Portfolio**: Represents legacy products that are still generating revenue [5] Focus Areas - The company targets two major disease states: cardiovascular disease and solid tumor cancer, which are leading causes of mortality globally [5][6] Product Highlights - **Auryon**: Launched in September 2020, this product has generated over $60 million in revenue in its second year, capturing market share from major competitors [7][8] - **AlphaVac**: A new product for treating pulmonary embolism (PE), designed to safely remove clots from patients [10][11] - **NanoKnife**: A device for treating intermediate-risk prostate cancer, recently received FDA clearance and CPT-1 code for reimbursement [19][21] Market Potential - The prostate cancer market is significant, with 300,000 diagnoses expected in the U.S. this year, and nearly half classified as intermediate risk [19] - The benign prostatic hyperplasia (BPH) market is larger than the prostate cancer market, presenting further growth opportunities [26] Financial Performance - The company is transitioning to positive EBITDA and cash flow, with zero debt on the balance sheet [29][42] - Recent financial results exceeded Wall Street expectations, with guidance raised in several categories [30][42] Future Growth Strategy - AngioDynamics plans to leverage existing technologies to expand into new markets without relying heavily on M&A [47][50] - The company aims to increase its market presence in thrombectomy and coronary markets, which are larger than current markets [39][40][41] Management Transition - CEO Jim Clemmer announced his retirement, which may have impacted stock performance, but he expressed confidence in the company's future [32][53] Additional Important Information - The company has been recognized by Time Magazine as one of the top 25 medical inventions, highlighting the innovative nature of its products [24] - AngioDynamics is focusing on education and awareness campaigns to promote its new treatment options, particularly NanoKnife [22][23] This summary encapsulates the key points discussed during the AngioDynamics FY Conference Call, highlighting the company's strategic transformation, product innovations, market opportunities, and financial outlook.